Breast cancer is still the most widely seen type of cancer globally. According to the statistics from Breastcancer.org, an estimated 231,840 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S. in 2015, along with 60,290 new cases of non-invasive breast cancer.
Early and reliable diagnosis is the key to increasing the chances of survival. However, mammography with 2D imaging can be unclear, especially in dense breast tissues. Unclear images can in turn, lead to cancer being missed.
A pioneer in 3D imaging, Siemens has introduced True Breast Tomosynthesis to overcome this problem and deliver greater certainty. This 3D option with the Siemens MAMMOMAT Inspiration mammography platform detects 43% more breast cancers than traditional mammography, according to the study conducted by the Lund University in Malmö, Sweden.
How does it work? By acquiring and combining breast images from multiple angles over 50°, True Breast Tomosynthesis creates a 3D volume of the entire breast. This is displayed in slices, thereby reducing the impact of overlapping breast tissue, which is a common problem with conventional 2D mammography. It comes with a total of 25 projections and allows:
• Safer diagnosis
• Improved early stage detection rate
• Reduced tissue overlap
• 3D visualization of micro-calcifications, shape and size of lesions
• High depth and contrast resolution
The 3D X-ray technique is also more comfortable for patients as breast compression is halved. Compared to traditional mammography, this technique also involves shorter reading times, lower radiation doses and reduced discomfort and pain. Reduced patient discomfort can encourage higher participation in future screening programs.
The MAMMOMAT Inspiration with tomosynthesis Option was recently approved by the US Food and Drug Administration (FDA).
Gregory Sorensen, MD, president and CEO of Siemens Healthcare North America said, “With the FDA approval of the MAMMOMAT Inspiration with Tomosynthesis Option, Siemens Healthcare reaffirms its longstanding commitment to cutting-edge innovation in women’s health.”